Calidi Biotherapeutics Secures $7.5 Million Through Stock Offering

Calidi Biotherapeutics Public Offering Overview

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnology firm focused on innovative cancer immunotherapies, has recently announced the pricing of a significant public offering. This offering includes 4,437,869 shares of its common stock, each priced at $1.69. The initiative marks a critical milestone for the company as it seeks to advance its mission of developing advanced treatment options for cancer.

Proceeds and Expectations

The anticipated proceeds from this offering are approximately $7.5 million, set aside for essential purposes including working capital, general corporate needs, and the support of pre-clinical and clinical trials. This strategic allocation of funding reinforces Calidi's commitment to its innovative therapies that harness the power of the immune system to combat various cancers.

Details of the Offering

Expected to close soon, the public offering is contingent on customary closing conditions. Ladenburg Thalmann & Co. Inc. is designated as the exclusive placement agent for this transaction, ensuring a smooth process as Calidi moves forward with its growth plans.

Registration Framework

The shares offered are registered under a shelf registration statement on Form S-3 (File No. 333-282456), which the U.S. Securities and Exchange Commission (SEC) declared effective earlier. The offering will be conducted strictly in accordance with the registered prospectus, ensuring complete transparency and compliance for potential investors.

Company Mission and Technology

Calidi Biotherapeutics is at the forefront of immuno-oncology innovation, focusing on proprietary technologies that empower the immune system to fight off cancer cells effectively. The company's unique platforms use potent allogeneic stem cells designed to deliver oncolytic viruses, providing promising avenues for treating conditions like high-grade gliomas and various solid tumors.

Innovative Approach to Cancer Treatment

The company's pioneering dual approach leverages off-the-shelf, universal cell-based delivery systems that safeguard and amplify the effectiveness of oncolytic viruses. This strategy aims not only to enhance the efficacy of treatments but also to improve patient safety outcomes, marking a significant advancement in cancer therapy.

Future Directions

As Calidi Biotherapeutics continues to grow, the recent public offering will play a crucial role in funding ongoing and future clinical trials. The company is committed to advancing its research and development efforts, ensuring that it remains a leader in the biotechnology field. This funding will enable Calidi to move forward with its clinical trial programs, further validating its technology and expanding its portfolio of treatment options.

Connecting with Calidi Biotherapeutics

For those interested in learning more about Calidi Biotherapeutics, the company encourages visitors to its official website for further insights into its groundbreaking work and ongoing projects. The firm is dedicated to transparency and communication with its stakeholders, fostering an environment of trust and engagement.

Frequently Asked Questions

What is the purpose of Calidi Biotherapeutics' public offering?

The public offering aims to raise approximately $7.5 million for working capital and support for pre-clinical and clinical trials.

Who is managing the stock offering?

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the public offering.

What type of cancer therapies does Calidi develop?

Calidi focuses on targeted immunotherapies using stem cell technology to deliver oncolytic viruses for various cancer types.

How does Calidi enhance patient safety with its treatments?

The company's platforms aim to protect and amplify oncolytic viruses, leading to improved safety and efficacy in treatments.

How can I find more information about Calidi Biotherapeutics?

More information is available on Calidi Biotherapeutics' official website, where you can learn about their technology and ongoing projects.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.